DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. It is illegal to introduce this substance into the body. Only licensed professionals should handle it. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
CJC-1295 (No DAC)+Ipamorelin+Tesamorelin
CJC-1295 without Drug Affinity Complex (no DAC) is a short-acting analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern. Ipamorelin is a selective growth hormone secretagogue (GHS) that activates ghrelin receptors to increase GH secretion without significantly affecting cortisol or prolactin. Tesamorelin is a stabilized 44–amino acid GHRH analog that increases GH release and is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. In research settings, this combination is explored for its potential to enhance GH output, IGF-1 production, and tissue recovery through multiple complementary pathways.
Currently unavailable. Please check back soon or contact us for more information.
What is CJC-1295 (No DAC)+Ipamorelin+Tesamorelin?
CJC-1295 without Drug Affinity Complex (no DAC) is a short-acting analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern. Ipamorelin is a selective growth hormone secretagogue (GHS) that activates ghrelin receptors to increase GH secretion without significantly affecting cortisol or prolactin. Tesamorelin is a stabilized 44–amino acid GHRH analog that increases GH release and is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. In research settings, this combination is explored for its potential to enhance GH output, IGF-1 production, and tissue recovery through multiple complementary pathways.
Mechanisms of Action
CJC-1295 (no DAC) + Ipamorelin + Tesamorelin may work together by:
CJC-1295 (no DAC): Binding to GHRH receptors to produce short bursts of GH that mimic physiologic release
Ipamorelin: Activating ghrelin receptors (GHS-R1a) to trigger GH release without large increases in cortisol or prolactin
Tesamorelin: Stimulating GHRH receptors with a longer-acting profile, increasing GH secretion and promoting fat metabolism
Increasing circulating IGF-1 to support protein synthesis, collagen formation, and tissue regeneration
Supporting muscle preservation, fat utilization, and connective tissue health in research models
Combining short-acting (CJC-1295 no DAC) and longer-acting (Tesamorelin) GHRH analogs for layered GH stimulation